FDA has granted candidate CFT7455 from C4 Therapeutics orphan drug status. CFT7455 is being developed to treat multiple myeloma. The drug could also be used to treat non-Hodgkin's lymphoma, including peripheral T-cell lymphoma and mantle cell lymphoma. In June, the company initiated a phase 1/2 clinical trial in which it plans to enroll 160 participants.